Immagina Biotechnology has developed a patented technology called RiboLace that enables users to better understand cellular function, with applications in personalized medicine research. Its products can be acquired by research labs and pharmaceutical companies to develop drugs that modify RNA gene expression. The company is advancing studies in cancer and neurodegenerative diseases. Immagina intends to use the recently raised funds to continue developing its technology. Founded in 2014 by Massimiliano Clamer following research at the University of Trento’s Center for Integrated Biologics and CNR‑IBF, the company is based in Trento, Italy. The report does not disclose operating metrics such as revenue or user numbers.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2016